Additional Information

Description

Genvoya® is a fixed-dose combination tablet containing elvitegravir (150 mg), cobicistat (150 mg), emtricitabine (200 mg), and tenofovir alafenamide (10 mg). Genvoya® can be used as a complete regimen for treatment-naïve patients or as a replacement therapy for patients who are virologically suppressed on a stable antiretroviral (ARV) regimen for at least 6 months, with no history of treatment failure or resistance to any of the components.

Each tablet is green, capsule-shaped, and film-coated, with "GSI" debossed on one side and "510" on the other. Genvoya® works by combining the actions of four antiretroviral agents: elvitegravir inhibits the integrase enzyme, cobicistat acts as a pharmacokinetic enhancer to boost elvitegravir levels, while emtricitabine and tenofovir alafenamide are nucleoside reverse transcriptase inhibitors (NRTIs) that prevent viral replication.

The recommended dosage of Genvoya® is one tablet taken once daily with food. It is important to adhere to the prescribed regimen to maintain viral suppression and prevent the development of resistance. Regular monitoring of kidney function and liver enzymes is recommended, as adverse effects may occur.